Viking Therapeutics, Inc. (0VQA.L)
USD 39.07
(-17.95%)
USD 39.07
(-17.95%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -100.82 Million USD | -43.31% |
| 2022 | -70.35 Million USD | -26.35% |
| 2021 | -55.68 Million USD | -30.52% |
| 2020 | -42.66 Million USD | -30.52% |
| 2019 | -32.68 Million USD | -24.95% |
| 2018 | -26.16 Million USD | -37.18% |
| 2017 | -19.07 Million USD | -37.72% |
| 2016 | -13.84 Million USD | -15.43% |
| 2015 | -11.99 Million USD | 48.88% |
| 2014 | -23.46 Million USD | -23118.16% |
| 2013 | -101.07 Thousand USD | -22947.04% |
| 2012 | -438.56 USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -34.07 Million USD | -16.35% |
| 2024 Q2 | -34.05 Million USD | 0.06% |
| 2024 Q3 | -36.55 Million USD | -7.35% |
| 2023 Q1 | -20.53 Million USD | -1.25% |
| 2023 Q3 | -27.26 Million USD | -14.85% |
| 2023 Q2 | -23.74 Million USD | -15.6% |
| 2023 Q4 | -29.28 Million USD | -7.41% |
| 2023 FY | -100.82 Million USD | -43.31% |
| 2022 Q4 | -20.28 Million USD | -25.23% |
| 2022 Q2 | -17.63 Million USD | -8.53% |
| 2022 Q1 | -16.24 Million USD | -29.86% |
| 2022 FY | -70.35 Million USD | -26.35% |
| 2022 Q3 | -16.19 Million USD | 8.14% |
| 2021 FY | -55.68 Million USD | -30.52% |
| 2021 Q3 | -13.4 Million USD | 13.76% |
| 2021 Q1 | -14.22 Million USD | -26.3% |
| 2021 Q2 | -15.54 Million USD | -9.23% |
| 2021 Q4 | -12.51 Million USD | 6.66% |
| 2020 FY | -42.66 Million USD | -30.52% |
| 2020 Q4 | -11.26 Million USD | -14.45% |
| 2020 Q3 | -9.84 Million USD | 7.19% |
| 2020 Q2 | -10.6 Million USD | 3.12% |
| 2020 Q1 | -10.94 Million USD | -23.39% |
| 2019 FY | -32.68 Million USD | -24.95% |
| 2019 Q4 | -8.87 Million USD | -19.28% |
| 2019 Q3 | -7.43 Million USD | 22.26% |
| 2019 Q2 | -9.56 Million USD | -40.6% |
| 2019 Q1 | -6.8 Million USD | 3.28% |
| 2018 Q2 | -6.92 Million USD | -44.12% |
| 2018 FY | -26.16 Million USD | -37.18% |
| 2018 Q4 | -7.03 Million USD | 4.83% |
| 2018 Q3 | -7.39 Million USD | -6.77% |
| 2018 Q1 | -4.8 Million USD | -8.53% |
| 2017 Q4 | -4.42 Million USD | 5.63% |
| 2017 Q3 | -4.69 Million USD | 5.84% |
| 2017 Q2 | -4.98 Million USD | -0.28% |
| 2017 Q1 | -4.96 Million USD | -32.94% |
| 2017 FY | -19.07 Million USD | -37.72% |
| 2016 Q3 | -3.26 Million USD | 8.77% |
| 2016 FY | -13.84 Million USD | -15.43% |
| 2016 Q1 | -3.26 Million USD | 29.28% |
| 2016 Q2 | -3.57 Million USD | -9.51% |
| 2016 Q4 | -3.73 Million USD | -14.5% |
| 2015 Q1 | -461.04 Thousand USD | -30.4% |
| 2015 Q2 | -2.62 Million USD | -469.78% |
| 2015 Q4 | -4.62 Million USD | -7.74% |
| 2015 Q3 | -4.28 Million USD | -63.24% |
| 2015 FY | -11.99 Million USD | 48.88% |
| 2014 Q1 | -209.73 Thousand USD | -418.32% |
| 2014 Q2 | -21.75 Million USD | -10272.82% |
| 2014 Q3 | -1.14 Million USD | 94.72% |
| 2014 Q4 | -353.56 Thousand USD | 69.23% |
| 2014 FY | -23.46 Million USD | -23118.16% |
| 2013 Q1 | -3190.00 USD | 97.09% |
| 2013 Q3 | -40.46 Thousand USD | -138.65% |
| 2013 Q4 | -40.46 Thousand USD | 0.0% |
| 2013 Q2 | -16.95 Thousand USD | -431.54% |
| 2013 FY | -101.07 Thousand USD | -22947.04% |
| 2012 Q4 | -109.64 Thousand USD | 0.0% |
| 2012 FY | -438.56 USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -169.18 Million USD | 40.403% |
| Dynavax Technologies Corporation | -37.02 Million USD | -172.299% |
| Supernus Pharmaceuticals, Inc. | -5.26 Million USD | -1813.589% |
| Perrigo Company plc | 151.9 Million USD | 166.377% |
| Illumina, Inc. | -1.06 Billion USD | 90.568% |
| Thermo Fisher Scientific Inc. | 6.85 Billion USD | 101.47% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 78.108% |
| Walgreens Boots Alliance, Inc. | -14.07 Billion USD | 99.284% |
| IQVIA Holdings Inc. | 1.97 Billion USD | 105.1% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 8.849% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 102.491% |
| Unity Biotechnology, Inc. | -44.66 Million USD | -125.73% |
| Waters Corporation | 817.67 Million USD | 112.331% |
| Biogen Inc. | 1.29 Billion USD | 107.775% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 63.202% |
| Evolus, Inc. | -49.23 Million USD | -104.796% |
| Adicet Bio, Inc. | -152.03 Million USD | 33.683% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 17.011% |
| bluebird bio, Inc. | -244.26 Million USD | 58.722% |
| Esperion Therapeutics, Inc. | -155.56 Million USD | 35.186% |
| FibroGen, Inc. | -281.81 Million USD | 64.222% |
| Agilent Technologies, Inc. | 1.35 Billion USD | 107.469% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | -123.676% |
| Homology Medicines, Inc. | -48.25 Million USD | -108.946% |
| Geron Corporation | -193.94 Million USD | 48.012% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 64.268% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | -37.191% |
| Myriad Genetics, Inc. | -123.7 Million USD | 18.491% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 80.433% |
| Zoetis Inc. | 3.06 Billion USD | 103.285% |
| Abeona Therapeutics Inc. | -48.2 Million USD | -109.185% |
| Mettler-Toledo International Inc. | 1.08 Billion USD | 109.273% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 151.855% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 102.341% |
| Kala Pharmaceuticals, Inc. | -39.15 Million USD | -157.52% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 71.496% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 63.469% |
| Verastem, Inc. | -92.08 Million USD | -9.495% |
| Nektar Therapeutics | -137.42 Million USD | 26.631% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 56.507% |
| Aclaris Therapeutics, Inc. | -97.35 Million USD | -3.564% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 62.353% |
| OPKO Health, Inc. | -157.02 Million USD | 35.788% |
| Exelixis, Inc. | 170.88 Million USD | 159.003% |
| Neurocrine Biosciences, Inc. | 250.9 Million USD | 140.186% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 193.983% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -80.836% |
| uniQure N.V. | -282.87 Million USD | 64.356% |
| Imunon, Inc. | -21.03 Million USD | -379.434% |
| Blueprint Medicines Corporation | -486.27 Million USD | 79.266% |
| Insmed Incorporated | -709.62 Million USD | 85.792% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 129.868% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 74.245% |
| TG Therapeutics, Inc. | 20.63 Million USD | 588.669% |
| Incyte Corporation | 620.52 Million USD | 116.249% |
| Emergent BioSolutions Inc. | -726.4 Million USD | 86.12% |